nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

18.05.2017 | Letter to the Editor

FDG PET for therapy monitoring in Hodgkin’s and non-Hodgkin’s lymphomas: qPET versus rPET

verfasst von: Eric Laffon, Roger Marthan

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Nur mit Berechtigung zugänglich

Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017; doi:10.1007/s00259-017-3690-8.

Hasenclever D, Kurch L, Mauz-Körholz, et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.CrossRefPubMed

Annunziata S, Cuccaro A, Calcagni ML, Hohaus S, Giordano A, Rufini V. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30:588–92.CrossRefPubMed

Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging. 2014;41:2154.CrossRefPubMed

Hasenclever D, Kurch L, Kluge R. Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan. Eur J Nucl Med Mol Imaging. 2014;41:2155–7.CrossRefPubMed

Laffon E, Milpied N, Marthan R. Measurement uncertainty of lesion and reference mediastinum SUV in lung cancer. Nucl Med Commun. 2017. Accepted for publication.

Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high–tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618–26.CrossRef

JCGM 2008. Evaluation of measurement data - Guide to the expression of uncertainty in measurement. www.bipm.org. 2008.

Titel: FDG PET for therapy monitoring in Hodgkin’s and non-Hodgkin’s lymphomas: qPET versus rPET
verfasst von: Eric Laffon
Roger Marthan
Publikationsdatum: 18.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3719-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI

The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT

An insight into the EANM technologist committee benchmark document on nuclear medicine technologists’ competencies

FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer

Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate